Post by Antonio Maldonado

Artificial intelligence is enhancing the development of radiopharmaceuticals for cancer treatment by improving targeting and reducing safety concerns. Deep learning and generative AI can accelerate the discovery of stable, effective radiopharmaceuticals by identifying novel targets and optimizing drug structures. "The most exciting prospect is personalized theranostics supported by digital twins," said Sofia Michopoulo, head of Nuclear Medicine Physics at University Hospital Southampton.